An injectable drug called liraglutide, used to lower blood sugar levels, may help lower the risk of cardiovascular disease, such as stroke and heart attack, according to a recent study.
Liraglutide is a diabetes medication that has been used since 2009 in clinical settings. It is a glucagon, as is the peptide-1 receptor agonist, which lowers blood sugar and lowers body weight.
Study results were published in The Lancet Diabetes and Endocrinology Control diabetes had five times less chance of developing cardiovascular events over three years.
"Our study supports the cardiovascular effects of liraglutide in a broader, nondelected patient population and provides important confirmatory evidence from clinical routine," said Bjorn Pasternak, senior researcher at the Department of Medicine at Karolinska Institutet in Sweden.
"We believe this may be of interest to drug regulators, clinical guidelines, physicians and patients," added Pasternak.
The use of liraglutide has also been associated with reduced risk of cardiovascular death and any cause of death.
For the study, the team of researchers used several nationwide records of more than 46,000 patients with information on prescription drugs, diseases and other data in Sweden and Denmark between 201
Approximately 23,000 patients taking liraglutide for treatment Diabetes were compared with the same number of patients who received another diabetes drug, DPP4 inhibitors.
The study's findings focused mainly on cardiovascular events, defined as myocardial infarction, stroke or cardiovascular death.
In patients taking liraglutide and liraglutide, the rate of cardiovascular events was 14 15.4 per 1,000 patients on DPP4 inhibitors, a statistically significant difference, the researchers said.
Other Health News articles
For more related articles, download the OnlymyHealth app.